Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Drug Factories Ordered to Clean Up (China)

This article was originally published in PharmAsia News

Executive Summary

Up until now, intense market rivalry has kept environmental concerns from becoming a priority for the Chinese pharmaceutical industry. But according to the country's environmental protection officials, that is all about to change. On Sept. 5 representatives for the State Environmental Protection Administration announced that over half of the country's pharmaceutical companies are in danger of being closed due to excessive pollution. Since July, China's environmental protection agency has been specifically targeting drug companies as part of an effort to reduce pollution in the country's rivers. Of the list of 6,066 environmentally destructive companies identified, 117 were drug makers. Now these companies must clean up their act or join the 649 businesses that have already been shut down. (Click here for more

Latest Headlines
See All
UsernamePublicRestriction

Register

SC066503

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel